Sanofi, Carlyle vie for India's Elder Pharma buyout; China to punish 39 hospital employees for taking kickbacks;

@FiercePharma: Lilly sales up 6%, to $5.93B; Cymbalta up 22% (!). Too bad it gets generic rivals later this year. Release | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Special report on the projected top 20 orphan drugs of 2018... see who made the list. Feature | Follow @CarlyHFierce

> Sanofi ($SNY) and the private equity firm Carlyle Group are reportedly in rival talks to buy India's Elder Pharmaceuticals domestic drug business for up to $450 million. Report

> China plans to punish 39 hospital employees for taking illegal kickbacks from drugmakers as a corruption probe continues to widen beyond GlaxoSmithKline ($GSK). Report

> A U.S. appeals court slapped down the FDA's use of "enforcement discretion" to allow importation of unapproved versions of the execution drug thiopental, whose agency-reviewed version is no longer available in the U.S. Report

> The European Commission is investigating whether struggling German drugmakers have unfairly benefited from a rebate exemption. Report

> Cheered by Forest Laboratories' ($FRX) quarterly results announced Tuesday, investors bid up the stock by 2% by yesterday's close. Report

Medical Device News

@FierceMedDev: Special Report: Top 10 Med Tech Investments of Q2. Feature | Follow @FierceMedDev

@MarkHFierce: U.K. researchers believe that low levels of a specific protein can signify aggressive colorectal cancer. More | Follow @MarkHFierce

@DamianFierce: Fresh deals and booming sales have Illumina brightening its 2013 guidance. News | Follow @DamianFierce

> Boston Scientific rolls out new imaging catheter in U.S., EU and Japan. Article

> Thermo lands another record quarter with Life on horizon. More

> Bard's costly lawsuits drown profits in Q2. Report

> FDA warns Prodigy Diabetes Care over glucose testing systems. Item

Biotech News

@FierceBiotech: PR: Verastem receives orphan drug designation from the FDA for defactinib in mesothelioma. Release | Follow @FierceBiotech

@RyanMFierce: Roche highlights more upbeat PhIII data for 'breakthrough' leukemia contender. News | Follow @RyanMFierce

@EmilyMFierce: Scientists advocate for more responsible preclinical studies. Item | Follow @EmilyMFierce

> Pfizer licenses antibody tech from Atlas-backed startup Harbour. News

> Big Pharma agrees to widen access to clinical trial data. Report

> Merck advances cardio drug under FDA review. More

> Big Pharma agrees to widen access to clinical trial data. Story

> After FDA meeting, Sarepta plans fast filing for DMD drug eteplirsen. Report

Biomarkers News

> Epigenetic tags point to a new generation of age-related biomarkers. Report

> Nerves could predict aggressiveness of prostate cancer. More

> Takeda and Zinfandel advance Alzheimer's biomarker work. Story

> Plaque buildup trajectory may serve as a clue for Alzheimer's. Article

> Autism clues: UC Davis team spots two new potential biomarkers of the condition. Item

Drug Delivery News

 @MichaelGFierce: Regulus completes $49M public offering to support microRNA tech. Report | Follow @MichaelGFierce

> Novaliq secures CE mark for OTC drop to treat dry eye. News

> Supercomputer-designed hypertension drug mimics natural hormone response. Story

> Imprimis to begin osteoarthritis cream PhIII, snags transdermal wound treatment. More

> Cancer drug breaches blood-brain barrier using nanovesicles. Article

> Flowonix reports longest service life ever in 6-year Prometra trial. Item

And Finally... Breast cancer survival is three years shorter for black women compared with white women because of delayed diagnoses and treatment discrepancies. Report

Suggested Articles

Amid a tough fight in the blood thinner market, J&J and Bayer's Xarelto scored a trial win in treating PAD patients after a recent leg artery surgery.

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.